UK MHRA Finalizes Strategy For Embedding Patient And Public Voice In Its Work
The UK MHRA has pushed back the timelines for delivering some of the objectives listed in its first five-year strategy on involving patients and public in regulatory decision-making.
You may also be interested in...
In launching its latest consultation, the MHRA says it wants to see much more focus on the role of the ‘patient and public voice’ in shaping the way it makes regulatory decisions.
The EMA is inviting feedback on its plans to ratify, with some caveats, a new framework on how to use patient preferences as input in medical product decision-making. The framework was developed under the EU’s public-private Innovative Medicines Initiative.
The COVID-19 pandemic has given a new impetus to Sweden’s ongoing efforts to support decentralized clinical trials.